HWAM
CRVS icon

Hennion & Walsh Asset Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Hennion & Walsh Asset Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$607K Buy
+52,673
New +$734K 0.02% 705

Other funds holding CRVS

AIM
Avity Investment Management Greenwich, Connecticut $1.6B AUM 32.15% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Eastern Bank
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Hennion & Walsh Asset Management's CRVS Position: Q3 2026 in Review

Hennion & Walsh Asset Management opened a new position in Corvus Pharmaceuticals (CRVS) in Q3 2026: 52,673 shares worth $607K. The stake represents 0.02% of the portfolio and ranks #705 among its holdings.

6 funds tracked by Wall St. Rank hold CRVS as of Q3 2026.

  • Hennion & Walsh Asset Management held 52,673 shares of Corvus Pharmaceuticals worth $607K as of Q3 2026.
  • Corvus Pharmaceuticals was a new Hennion & Walsh Asset Management position in Q3 2026.
  • Corvus Pharmaceuticals made up 0.02% of Hennion & Walsh Asset Management's portfolio in Q3 2026, its #705 holding.
  • 6 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q3 2026, filed 13 Oct 2026.